Clinical trial
A Randomized Study to Evaluate FK962 in Subjects With Mild to Moderate…
NCT00087724 · Astellas Pharma Inc, Industry · Terminated
Key facts
| NCT number | NCT00087724 |
|---|---|
| Title | A Randomized Study to Evaluate FK962 in Subjects With Mild to Moderate Alzheimer's Disease |
| Official title | A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 2 Study to Evaluate the Safety and Efficacy of FK962 in Subjects With Mild to Moderate Alzheimer's Disease |
| Lead sponsor | Astellas Pharma Inc, Industry |
| Collaborators | Astellas Pharma US, Inc. Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Alzheimer's Disease |
| Intervention type | Drug |
| Interventions | FK962 |
| Enrollment | 510 |
| Start date | Jul 1, 2004 |
| Completion | Sep 1, 2006 |
| First posted | Jul 14, 2004 |
| Last update posted | Jun 7, 2012 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: